Premature Ejacualtion Market - Global Outlook and Forecast 2017 - 2022
Innovus Pharma, Plethora Solutions, Absorption Pharmaceuticals and Allergan are the leading companies dominating the premature ejaculation market. The global premature ejaculation (PE) market is expected to cross $1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016−2022. A high burden of PE prevalence and associated chronic condition, which can, in turn, poses as a high-risk factor for the occurrence of this disease is the key market driver for the premature ejaculation market in both developing and developed countries. Regionally, the US is the main contributor to the global PE market. Despite the absence of PE drug in the US, the market in North America retains dominant share because of wide accessibility to PE off-labels and OTC drugs. In terms of route of administration, the oral drugs segment contributes a dominant share of nearly three-fourths of the global market.
Report Timeline
SCOPE OF THE REPORT
The report considers the present scenario of the global premature ejaculation market and its in-depth analysis for the period 2017–2022. It includes a detailed study of growth drivers, trends, and restraints. The report alsoprofiles the leading vendors in the market and other key vendors.
The report provides the analysis of key segments of the market by route administration, mechanism of action, geography, and vendors. It provides a detailed analysis of revenue from various segments:
Route Administration
Premature ejaculation (PE) is a male sexual dysfunction, which is characterized by the inability to delay ejaculation for more than one minute after penetration or sexual stimulation. The condition is associated with uncontrolled ejaculation either before or shortly after sexual penetration, or with minimal sexual stimulation.
The global premature ejaculation market is expected to cross $1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016−2022. Increasing disease awareness, growing patient willingness to seek pharmaceutical therapy assistance for disease management and increasing presence of favorable guidelines, which recommended the use of drugs as first-line therapy for treatment of PE, will augment market prospects during the forecast period.
The report provides a holistic view of the global premature ejaculation market, the companies involved in the market, and the factors driving its growth. The report alsoprovides information about the latest trends that are likely to become strong market driving forces over the next five years. This report alsoprovides the Porter’s Five Forces analysis along with a description of each force and its impact on the market. Further, the report alsoprovides complete value chain analysis of the global market.
Premature Ejaculation Market Dynamics
Emphasis on clinical progress of love hormone receptor antagonists to drive the market growth
Increase in prevalence of chronic diseases, low-effectiveness of non-pharmacological treatment, and a wide accessibility to premature ejaculation OTC drugs and generic off-label drugs are the prime factors that are going to escalate the market growth during the forecast period. Furthermore, pharmaceutical advances in PE drug formulation technology, emphasis on clinical progress of love hormone receptor antagonists, and launch of premature ejaculation treatment awareness campaigns are the latest trends that are likely to positively impact the market. The report alsoprovides the key restraints of the market.
Premature Ejaculation Market: Segmental Overview
The amide anesthetics segment is the fast-growing segment in terms of mechanism of action.
The oral drug segment to remain the dominant market in terms of route of administration. The topical PE drugs market is expected to witness growth at a higher pace than the oral PE drugs market. However, the oral PE drugs market is likely to retain its market share until the end of the forecast period.
In terms of mechanism of action (MOA), the global PE market broad segments include SSRIs, PDE5 inhibitors, and amide anesthetics. In 2016, the SSRIs segment dominated the market. This segment is anticipated to retain its dominance till the end of forecast period. The amide anesthetics segment, which occupied low share in 2016, is anticipated to witness higher growth than the other drug MOAs segment during the period 2016-2022.
Premature Ejaculation Market: Geographical Analysis
North America to remain the largest market followed by Europe
The premature ejaculation market in North America is the largest due to high prevalent PE population. The US occupies approximately 90% of the PE market in North America due to the high population density and comparably higher utilization of off-label and OTC PE products. Similarly, the UK, Germany, France, Spain, and Italy are the leading markets for PE therapies in the European region. The market in APAC is likely to witness the highest growth rate during the forecast period. A significant increase in PE incidence due to growing burden of chronic conditions, which, in turn, is associated with the high risk of PE occurrence is expected to boost the market growth in this region. The prevalence of PE in the Middle East countries and Latin America is estimated to be lowest than other regions. The market, however, is anticipated to witness a moderate growth rate in these regions.
Report Timeline
- Base Year: 2016
- Forecast Year: 2017−2022
- Innovus Pharma
- Plethora Solutions
- Absorption Pharmaceuticals
- Allergan
SCOPE OF THE REPORT
The report considers the present scenario of the global premature ejaculation market and its in-depth analysis for the period 2017–2022. It includes a detailed study of growth drivers, trends, and restraints. The report alsoprofiles the leading vendors in the market and other key vendors.
The report provides the analysis of key segments of the market by route administration, mechanism of action, geography, and vendors. It provides a detailed analysis of revenue from various segments:
Route Administration
- Topical therapies
- Oral therapy
- SSRI
- PDE5 inhibitors
- Ester/Amide anesthetics
- APAC
- Europe
- Latin America
- MEA
- North America
Premature ejaculation (PE) is a male sexual dysfunction, which is characterized by the inability to delay ejaculation for more than one minute after penetration or sexual stimulation. The condition is associated with uncontrolled ejaculation either before or shortly after sexual penetration, or with minimal sexual stimulation.
The global premature ejaculation market is expected to cross $1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016−2022. Increasing disease awareness, growing patient willingness to seek pharmaceutical therapy assistance for disease management and increasing presence of favorable guidelines, which recommended the use of drugs as first-line therapy for treatment of PE, will augment market prospects during the forecast period.
The report provides a holistic view of the global premature ejaculation market, the companies involved in the market, and the factors driving its growth. The report alsoprovides information about the latest trends that are likely to become strong market driving forces over the next five years. This report alsoprovides the Porter’s Five Forces analysis along with a description of each force and its impact on the market. Further, the report alsoprovides complete value chain analysis of the global market.
Premature Ejaculation Market Dynamics
Emphasis on clinical progress of love hormone receptor antagonists to drive the market growth
Increase in prevalence of chronic diseases, low-effectiveness of non-pharmacological treatment, and a wide accessibility to premature ejaculation OTC drugs and generic off-label drugs are the prime factors that are going to escalate the market growth during the forecast period. Furthermore, pharmaceutical advances in PE drug formulation technology, emphasis on clinical progress of love hormone receptor antagonists, and launch of premature ejaculation treatment awareness campaigns are the latest trends that are likely to positively impact the market. The report alsoprovides the key restraints of the market.
Premature Ejaculation Market: Segmental Overview
The amide anesthetics segment is the fast-growing segment in terms of mechanism of action.
The oral drug segment to remain the dominant market in terms of route of administration. The topical PE drugs market is expected to witness growth at a higher pace than the oral PE drugs market. However, the oral PE drugs market is likely to retain its market share until the end of the forecast period.
In terms of mechanism of action (MOA), the global PE market broad segments include SSRIs, PDE5 inhibitors, and amide anesthetics. In 2016, the SSRIs segment dominated the market. This segment is anticipated to retain its dominance till the end of forecast period. The amide anesthetics segment, which occupied low share in 2016, is anticipated to witness higher growth than the other drug MOAs segment during the period 2016-2022.
Premature Ejaculation Market: Geographical Analysis
North America to remain the largest market followed by Europe
The premature ejaculation market in North America is the largest due to high prevalent PE population. The US occupies approximately 90% of the PE market in North America due to the high population density and comparably higher utilization of off-label and OTC PE products. Similarly, the UK, Germany, France, Spain, and Italy are the leading markets for PE therapies in the European region. The market in APAC is likely to witness the highest growth rate during the forecast period. A significant increase in PE incidence due to growing burden of chronic conditions, which, in turn, is associated with the high risk of PE occurrence is expected to boost the market growth in this region. The prevalence of PE in the Middle East countries and Latin America is estimated to be lowest than other regions. The market, however, is anticipated to witness a moderate growth rate in these regions.
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 REPORT COVERAGE
4.1 Market Definition
4.2 Base Year
4.3 Scope of Study
4.3.1 Market Segmentation by Route of Administration
4.3.2 Market Segmentation by Mechanism of Action
4.3.3 Market Segmentation by Geography
5 REPORT ASSUMPTIONS & CAVEATS
5.1 Currency Conversion rate
5.2 Market Derivation
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 Definition Of Premature Ejaculation
7.2 Disease Overview
7.3 CLASSIFICATION OF Premature Ejaculation
7.3.1 Lifelong PE
7.3.2 Acquired PE
7.3.3 Variable PE
7.3.4 Subjective EjD
7.4 Symptoms Of Premature Ejaculation (Pe)
7.5 Aetiology OF Premature Ejaculation
7.5.1 Physiological Factors
7.5.2 Biological Factors
7.5.3 Genetic Factors
7.5.4 Co-morbidity
7.6 Epidemiology
8 ISSN GUIDELINES ON PE
8.1 Disease Assessment
8.1.1 Patient History
8.1.2 Physical Examination
8.1.3 Assessment Instruments
8.2 Treatment
8.2.1 Physiological Therapy
8.2.2 Behavioral Techniques
8.2.3 Pharmacological Treatment
9 CLINICAL TRIAL LANDSCAPE
9.1 Overview
9.1.1 Trial Subjects Selection Criteria
9.1.2 Trial Design Considerations
9.1.3 Trial Data Evaluation Considerations
9.2 Clinical Trial EndPoints
10 PIPELINE LANDSCAPE
10.1 Overview
10.2 Key Pipeline Drug Candidates
10.3 Dormant/Terminated/Withdrawn Drug Candidates
10.4 Key Product Profiles
10.5 Epelsiban
10.5.1 Overview
10.5.2 Product Profile
10.5.3 Future Outlook
10.6 IX-01
10.6.1 Overview
10.6.2 Product Profile
10.6.3 Future Outlook
10.7 DA-8031
10.7.1 Overview
10.7.2 Product Profile
10.7.3 Future Outlook
11 MARKETED PRODUCTS LANDSCAPE
11.1 overview
11.2 Recommended Marketed Drugs
12 MARKET DYNAMICS
12.1 Market Growth Enablers
12.1.1 Increase in Prevalence of Chronic Diseases
12.1.2 Low-effectiveness of Non-pharmacological PE Treatment
12.1.3 High Unmet Need
12.1.4 Wide Accessibility to PE OTC Drugs and Generic Off-label Drugs
12.1.5 YOY Impact of Market Enablers
12.2 Market Growth Restraints
12.2.1 Low Treatment Seeking Patient Pool
12.2.2 Associated Adverse Effects of PE Drugs
12.2.3 Clinical Trial Withdrawals/Terminations
12.2.4 YOY Impact of Market Restraints
12.3 Market Opportunities & Trends
12.3.1 Advances in PE Drug Formulation Technologies
12.3.2 Emphasis on Clinical Progress of Love Hormone Receptor Antagonists
12.3.3 Launch of PE Awareness Campaigns
12.3.4 YOY Impact of Trends and Opportunities
13 GLOBAL PREMATURE EJACULATION MARKET
13.1 market Overview
13.2 Market Size & Forecast
13.3 Porter’s Five Forces Analysis
13.3.1 Threat of New Entrants
13.3.2 Bargaining Power of Suppliers
13.3.3 Bargaining Power of Buyers
13.3.4 Threat of Substitutes
13.3.5 Competitive Rivalry
14 PREMATURE EJACULATION MARKET- BY ROUTE OF ADMINISTRATION
14.1 Segment Overview
14.2 PE ORAL THERAPY Market
14.3 PE TOPICAL THERAPY MARKET
15 PREMATURE EJACULATION MARKET - BY MECHANISM OF ACTION
15.1 Segment Overview
15.2 SSRI PE Therapy Market
15.2.1 Market Size & Forecast
15.3 PDE5i PE Therapy Market
15.3.1 Market Size & Forecast
15.4 AMIDE/ESTER ANESTHETIC PE Therapy Market
15.4.1 Market Size & Forecast
16 PREMATURE EJACULATION MARKET BY GEOGRAPHY
16.1 Market Overview
17 NORTH AMERICA: PREMATURE EJACULATION MARKET
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 US: Market Size & Forecast
17.3.2 Canada: Market Size & Forecast
17.4 Leading Trends, Enablers, and Restraints
18 EUROPE: PREMATURE EJACULATION MARKET
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Germany: Market Size & Forecast
18.3.2 UK: Market Size & Forecast
18.3.3 France: Market Size & Forecast
18.3.4 Spain and Italy: Market Size & Forecast
18.4 Leading Trends, Enablers, and Restraints
19 APAC: PREMATURE EJACULATION MARKET
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 Japan: Market Size & Forecast
19.3.2 Australia: Market Size & Forecast
19.3.3 China and India: Market Size & Forecast
19.4 Leading Trends, Enablers, and Restraints
20 LATIN AMERICA: PREMATURE EJACULATION MARKET
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Major Trends, Enablers, and Restraints
21 MEA: PREMATURE EJACULATION MARKET
21.1 Market Overview
21.2 Market Size & Forecast
21.3 Major Trends, Enablers, and Restraints
22 COMPETITIVE LANDSCAPE
22.1 Strategic Recommendation for Market Participants
23 KEY COMPANY PROFILES
23.1 Innovus Pharmaceuticals INC.
23.1.1 Strength Assessment
23.1.2 Strategy Assessment
23.1.3 Opportunity Assessment
23.2 Plethora Solutions Holdings PLC
23.2.1 Strength Assessment
23.2.2 Strategy Assessment
23.2.3 Opportunity Assessment
23.3 Absorption Pharmaceuticals LLC
23.3.1 Strength Assessment
23.3.2 Strategy Assessment
23.3.3 Opportunity Assessment
23.4 Allergen PLC
23.4.1 Strength Assessment
23.4.2 Strategy Assessment
23.4.3 Opportunity Assessment
24 OTHER PROMINENT COMPANIES
24.1 Menrnani
24.1.1 Strength Assessment
24.1.2 Strategy Assessment
24.1.3 Opportunity Assessment
24.2 GlaxoSmithKline plc
24.2.1 Strength Assessment
24.2.2 Strategy Assessment
24.2.3 Opportunity Assessment
24.3 Ixchelsis Ltd
24.3.1 Strength Assessment
24.3.2 Strategy Assessment
24.3.3 Opportunity Assessment
24.4 DONG-A- Pharmaceuticals Co. Ltd.
24.4.1 Strength Assessment
24.4.2 Strategy Assessment
24.4.3 Opportunity Assessment
24.5 NeuroHealing Pharmaceuticals Inc.
24.5.1 Strength Assessment
24.5.2 Strategy Assessment
24.5.3 Opportunity Assessment
25 REPORT SUMMARY
25.1 Key Takeaways
25.2 Qualitative Summary of Global PRE-Mature Ejaculation Market
25.3 Quantitative Summary of Global PRe-Mature Ejaculation Market
26 APPENDIX
26.1 List of Abbreviations
List Of Exhibits
Exhibit 1 Segmentation of Global PE Market
Exhibit 2 Market Size Calculation Approach 2016
Exhibit 3 Classification of PE
Exhibit 4 Differentiation of Symptoms in PE Sub-types
Exhibit 5 Common Causative Factors for PE
Exhibit 6 PE Prevalence Rate across Various Geographical Regions
Exhibit 7 ISSN Recommended Drug Classes for PE Treatment
Exhibit 8 PE Treatment Algorithm
Exhibit 9 Key Considerations of PE Clinical Trials
Exhibit 10 Key Primary/Secondary Endpoints in PE Clinical Trials
Exhibit 11 Key Hurdles in Research and Innovation of Breakthrough PE Drugs
Exhibit 12 Increase in Global Diabetes Prevalence by Region 2015–2040 (Million)
Exhibit 13 Increase in Global ED Prevalence 1995-2025 (Million)
Exhibit 14 Increase in Global Prostate Cancer Incidence by Region 2012–2020 (thousand)
Exhibit 15 Major Drawbacks of Non-pharmacological PE Treatments
Exhibit 16 PE OTC Drugs Marketing Channels
Exhibit 17 Major Factors Restricting PE Treatment Rate
Exhibit 18 Korean Nation-wide Survey Results 0n Urologists' PE Treatment Rates Per Week (in %) 2012
Exhibit 19 Key Issues Leading to Clinical Trial Terminations/Withdrawal
Exhibit 20 Global PE Market 2016–2022 ($ million)
Exhibit 21 Five Forces Analysis 2016
Exhibit 22 Global PE Market by Route of Administration
Exhibit 23 Percentage Share of Oral and Topical PE Drugs 2016 and 2022
Exhibit 24 Global PE Market by Route of Administration ($ million)
Exhibit 25 Comparison of Growth Rates of Oral and Topical PE Segments
Exhibit 26 Most Common Oral Therapy Drug Types
Exhibit 27 Benefits/Drawbacks Summary of Oral PE Drugs
Exhibit 28 Global PE Oral Therapy Market Size and Forecast ($ million) 2016–2022
Exhibit 29 Available Topical Forms of PE Topical Therapies
Exhibit 30 Benefits/Drawbacks Summary of Topical PE Drugs
Exhibit 31 Global PE Topical Therapy Market Size and Forecast ($ million)
Exhibit 32 Global PE Market by Mechanism of Action
Exhibit 33 Percentage Share of SSRIs, PDE5is, and Amide Anesthetics
Exhibit 34 Global PE Market Lucrativeness by Mechanism of Action
Exhibit 35 Global PE Market by Mechanism of Action ($ million)
Exhibit 36 Comparison of Varying Efficacy of Off-label SSRIs
Exhibit 37 Global SSRI PE Drugs Market Size and Forecast ($ million)
Exhibit 38 Major PDE5i Drug Brands as Off-label PE Medications
Exhibit 39 Global PDE5i PE Therapy Market Size and Forecast ($ million)
Exhibit 40 Common Active Ingredients in Amide Anesthetic PE Formulations
Exhibit 41 Global PDE5i PE Therapy Market Size and Forecast ($ million)
Exhibit 42 Mode of Action of SSRIs
Exhibit 43 Global PE Market by Geography
Exhibit 44 Global PE Market by Geography ($ million)
Exhibit 45 Market Revenue Growth Rates Comparison by Geography
Exhibit 46 Global PE Market Lucrativeness by Geography 2022
Exhibit 47 PE Market in North America by Country 2016
Exhibit 48 Prevalence of PE in North America
Exhibit 49 PE Market in North America 2016–2022 ($ million)
Exhibit 50 PE Market in US 2016–2022 ($ million)
Exhibit 51 PE Market in Canada 2016–2022 ($ million)
Exhibit 52 Key PE Market Dynamics in North America
Exhibit 53 PE Market in Europe by Country 2016
Exhibit 54 Prevalence Trend of Prostate Cancer Holding High Associated Risk for PE Incidence in Europe 2012–2020 (thousand)
Exhibit 55 PE Market in Europe ($ million)
Exhibit 56 PE Market in Germany 2016–2022 ($ million)
Exhibit 57 PE Market in UK ($ million)
Exhibit 58 PE Market in France ($ million)
Exhibit 59 PE Market in Italy ($ million)
Exhibit 60 PE Market in Spain ($ million)
Exhibit 61 Key PE Market Dynamics in Europe
Exhibit 62 PE Market in APAC ($ million)
Exhibit 63 PE Market in Japan 2016–2022 ($ million)
Exhibit 64 PE Market in Australia ($ million)
Exhibit 65 PE Market in China ($ million)
Exhibit 66 PE Market in India ($ million)
Exhibit 67 Key PE Market Dynamics in APAC
Exhibit 68 PE Market in Latin America ($ million)
Exhibit 69 Key PE Market Dynamics in Latin America
Exhibit 70 PE Market in MEA 2016–2022 ($ million)
Exhibit 71 Key PE Market Dynamics in Latin America
Exhibit 72 Strategic Recommendation for Market Participants
TABLES
Table 1 Key Geographies Definition
Table 2 Key Caveats
Table 3 Currency Conversion 2013−2016
Table 4 Early Definitions of Premature Ejaculation
Table 5 Summary of PE Epidemiology Studies
Table 6 Recommended/Optional Questions to Establish Diagnosis and Treatment of PE
Table 7 Summary of PE Validated Questionnaires
Table 8 Summary of Commonly Recommended PE Drugs
Table 9 Key Pipeline PE Drug Molecules
Table 10 Key Dormant/Terminated/Withdrawn PE Pipeline Drug Molecules
Table 11 Epelsiban Product Profile
Table 12 IX-01 Product Profile
Table 13 DA-8031 Product Profile
Table 14 Recommended Drugs for PE Treatment
Table 15 Major Unmet Need in PE Market
Table 16 YOY Impact of Market Enablers 2016–2022
Table 17 Key Terminated/Withdrawn Investigational PE Drugs
Table 18 YOY Impact of Market Restraints 2016–2022
Table 19 Marketed PE Drugs with Meter-Dose Delivery Systems
Table 20 Pipeline Oxytocin Receptor Antagonists
Table 21 YOY Impact of Trends and Opportunities 2016–2022
Table 22 Global PE Market by Route of Administration 2016–2022 ($ million)
Table 23 Key Topical Therapy PE Drugs by Type of Formulation
Table 24 Global PE Market by Mechanism of Action 2016–2022 ($ million)
Table 25 Commonly Used Topical PE OTC Ester/Amide Anesthetic
Table 26 Global PE Market by Geography 2016–2022 ($ million)
Table 27 Key PE Campaigns Launched in Europe
Table 28 Competitive Structure Analysis of Global PE Market 2016
Table 29 Therapeutic Area and Products of Innovus
Table 30 Qualitative Summary of Global PE Market
Table 31 Quantitative Summary of Global PE Market by Geography ($ million)
Table 32 Quantitative Summary of Global PE Market by Geography (Revenue %)
Table 33 Quantitative Summary of Global PE Market by Route of Administration ($ million)
Table 34 Quantitative Summary of Global PE Market by Mechanism of Action ($ million)
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 REPORT COVERAGE
4.1 Market Definition
4.2 Base Year
4.3 Scope of Study
4.3.1 Market Segmentation by Route of Administration
4.3.2 Market Segmentation by Mechanism of Action
4.3.3 Market Segmentation by Geography
5 REPORT ASSUMPTIONS & CAVEATS
5.1 Currency Conversion rate
5.2 Market Derivation
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 Definition Of Premature Ejaculation
7.2 Disease Overview
7.3 CLASSIFICATION OF Premature Ejaculation
7.3.1 Lifelong PE
7.3.2 Acquired PE
7.3.3 Variable PE
7.3.4 Subjective EjD
7.4 Symptoms Of Premature Ejaculation (Pe)
7.5 Aetiology OF Premature Ejaculation
7.5.1 Physiological Factors
7.5.2 Biological Factors
7.5.3 Genetic Factors
7.5.4 Co-morbidity
7.6 Epidemiology
8 ISSN GUIDELINES ON PE
8.1 Disease Assessment
8.1.1 Patient History
8.1.2 Physical Examination
8.1.3 Assessment Instruments
8.2 Treatment
8.2.1 Physiological Therapy
8.2.2 Behavioral Techniques
8.2.3 Pharmacological Treatment
9 CLINICAL TRIAL LANDSCAPE
9.1 Overview
9.1.1 Trial Subjects Selection Criteria
9.1.2 Trial Design Considerations
9.1.3 Trial Data Evaluation Considerations
9.2 Clinical Trial EndPoints
10 PIPELINE LANDSCAPE
10.1 Overview
10.2 Key Pipeline Drug Candidates
10.3 Dormant/Terminated/Withdrawn Drug Candidates
10.4 Key Product Profiles
10.5 Epelsiban
10.5.1 Overview
10.5.2 Product Profile
10.5.3 Future Outlook
10.6 IX-01
10.6.1 Overview
10.6.2 Product Profile
10.6.3 Future Outlook
10.7 DA-8031
10.7.1 Overview
10.7.2 Product Profile
10.7.3 Future Outlook
11 MARKETED PRODUCTS LANDSCAPE
11.1 overview
11.2 Recommended Marketed Drugs
12 MARKET DYNAMICS
12.1 Market Growth Enablers
12.1.1 Increase in Prevalence of Chronic Diseases
12.1.2 Low-effectiveness of Non-pharmacological PE Treatment
12.1.3 High Unmet Need
12.1.4 Wide Accessibility to PE OTC Drugs and Generic Off-label Drugs
12.1.5 YOY Impact of Market Enablers
12.2 Market Growth Restraints
12.2.1 Low Treatment Seeking Patient Pool
12.2.2 Associated Adverse Effects of PE Drugs
12.2.3 Clinical Trial Withdrawals/Terminations
12.2.4 YOY Impact of Market Restraints
12.3 Market Opportunities & Trends
12.3.1 Advances in PE Drug Formulation Technologies
12.3.2 Emphasis on Clinical Progress of Love Hormone Receptor Antagonists
12.3.3 Launch of PE Awareness Campaigns
12.3.4 YOY Impact of Trends and Opportunities
13 GLOBAL PREMATURE EJACULATION MARKET
13.1 market Overview
13.2 Market Size & Forecast
13.3 Porter’s Five Forces Analysis
13.3.1 Threat of New Entrants
13.3.2 Bargaining Power of Suppliers
13.3.3 Bargaining Power of Buyers
13.3.4 Threat of Substitutes
13.3.5 Competitive Rivalry
14 PREMATURE EJACULATION MARKET- BY ROUTE OF ADMINISTRATION
14.1 Segment Overview
14.2 PE ORAL THERAPY Market
14.3 PE TOPICAL THERAPY MARKET
15 PREMATURE EJACULATION MARKET - BY MECHANISM OF ACTION
15.1 Segment Overview
15.2 SSRI PE Therapy Market
15.2.1 Market Size & Forecast
15.3 PDE5i PE Therapy Market
15.3.1 Market Size & Forecast
15.4 AMIDE/ESTER ANESTHETIC PE Therapy Market
15.4.1 Market Size & Forecast
16 PREMATURE EJACULATION MARKET BY GEOGRAPHY
16.1 Market Overview
17 NORTH AMERICA: PREMATURE EJACULATION MARKET
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 US: Market Size & Forecast
17.3.2 Canada: Market Size & Forecast
17.4 Leading Trends, Enablers, and Restraints
18 EUROPE: PREMATURE EJACULATION MARKET
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 Germany: Market Size & Forecast
18.3.2 UK: Market Size & Forecast
18.3.3 France: Market Size & Forecast
18.3.4 Spain and Italy: Market Size & Forecast
18.4 Leading Trends, Enablers, and Restraints
19 APAC: PREMATURE EJACULATION MARKET
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 Japan: Market Size & Forecast
19.3.2 Australia: Market Size & Forecast
19.3.3 China and India: Market Size & Forecast
19.4 Leading Trends, Enablers, and Restraints
20 LATIN AMERICA: PREMATURE EJACULATION MARKET
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Major Trends, Enablers, and Restraints
21 MEA: PREMATURE EJACULATION MARKET
21.1 Market Overview
21.2 Market Size & Forecast
21.3 Major Trends, Enablers, and Restraints
22 COMPETITIVE LANDSCAPE
22.1 Strategic Recommendation for Market Participants
23 KEY COMPANY PROFILES
23.1 Innovus Pharmaceuticals INC.
23.1.1 Strength Assessment
23.1.2 Strategy Assessment
23.1.3 Opportunity Assessment
23.2 Plethora Solutions Holdings PLC
23.2.1 Strength Assessment
23.2.2 Strategy Assessment
23.2.3 Opportunity Assessment
23.3 Absorption Pharmaceuticals LLC
23.3.1 Strength Assessment
23.3.2 Strategy Assessment
23.3.3 Opportunity Assessment
23.4 Allergen PLC
23.4.1 Strength Assessment
23.4.2 Strategy Assessment
23.4.3 Opportunity Assessment
24 OTHER PROMINENT COMPANIES
24.1 Menrnani
24.1.1 Strength Assessment
24.1.2 Strategy Assessment
24.1.3 Opportunity Assessment
24.2 GlaxoSmithKline plc
24.2.1 Strength Assessment
24.2.2 Strategy Assessment
24.2.3 Opportunity Assessment
24.3 Ixchelsis Ltd
24.3.1 Strength Assessment
24.3.2 Strategy Assessment
24.3.3 Opportunity Assessment
24.4 DONG-A- Pharmaceuticals Co. Ltd.
24.4.1 Strength Assessment
24.4.2 Strategy Assessment
24.4.3 Opportunity Assessment
24.5 NeuroHealing Pharmaceuticals Inc.
24.5.1 Strength Assessment
24.5.2 Strategy Assessment
24.5.3 Opportunity Assessment
25 REPORT SUMMARY
25.1 Key Takeaways
25.2 Qualitative Summary of Global PRE-Mature Ejaculation Market
25.3 Quantitative Summary of Global PRe-Mature Ejaculation Market
26 APPENDIX
26.1 List of Abbreviations
List Of Exhibits
Exhibit 1 Segmentation of Global PE Market
Exhibit 2 Market Size Calculation Approach 2016
Exhibit 3 Classification of PE
Exhibit 4 Differentiation of Symptoms in PE Sub-types
Exhibit 5 Common Causative Factors for PE
Exhibit 6 PE Prevalence Rate across Various Geographical Regions
Exhibit 7 ISSN Recommended Drug Classes for PE Treatment
Exhibit 8 PE Treatment Algorithm
Exhibit 9 Key Considerations of PE Clinical Trials
Exhibit 10 Key Primary/Secondary Endpoints in PE Clinical Trials
Exhibit 11 Key Hurdles in Research and Innovation of Breakthrough PE Drugs
Exhibit 12 Increase in Global Diabetes Prevalence by Region 2015–2040 (Million)
Exhibit 13 Increase in Global ED Prevalence 1995-2025 (Million)
Exhibit 14 Increase in Global Prostate Cancer Incidence by Region 2012–2020 (thousand)
Exhibit 15 Major Drawbacks of Non-pharmacological PE Treatments
Exhibit 16 PE OTC Drugs Marketing Channels
Exhibit 17 Major Factors Restricting PE Treatment Rate
Exhibit 18 Korean Nation-wide Survey Results 0n Urologists' PE Treatment Rates Per Week (in %) 2012
Exhibit 19 Key Issues Leading to Clinical Trial Terminations/Withdrawal
Exhibit 20 Global PE Market 2016–2022 ($ million)
Exhibit 21 Five Forces Analysis 2016
Exhibit 22 Global PE Market by Route of Administration
Exhibit 23 Percentage Share of Oral and Topical PE Drugs 2016 and 2022
Exhibit 24 Global PE Market by Route of Administration ($ million)
Exhibit 25 Comparison of Growth Rates of Oral and Topical PE Segments
Exhibit 26 Most Common Oral Therapy Drug Types
Exhibit 27 Benefits/Drawbacks Summary of Oral PE Drugs
Exhibit 28 Global PE Oral Therapy Market Size and Forecast ($ million) 2016–2022
Exhibit 29 Available Topical Forms of PE Topical Therapies
Exhibit 30 Benefits/Drawbacks Summary of Topical PE Drugs
Exhibit 31 Global PE Topical Therapy Market Size and Forecast ($ million)
Exhibit 32 Global PE Market by Mechanism of Action
Exhibit 33 Percentage Share of SSRIs, PDE5is, and Amide Anesthetics
Exhibit 34 Global PE Market Lucrativeness by Mechanism of Action
Exhibit 35 Global PE Market by Mechanism of Action ($ million)
Exhibit 36 Comparison of Varying Efficacy of Off-label SSRIs
Exhibit 37 Global SSRI PE Drugs Market Size and Forecast ($ million)
Exhibit 38 Major PDE5i Drug Brands as Off-label PE Medications
Exhibit 39 Global PDE5i PE Therapy Market Size and Forecast ($ million)
Exhibit 40 Common Active Ingredients in Amide Anesthetic PE Formulations
Exhibit 41 Global PDE5i PE Therapy Market Size and Forecast ($ million)
Exhibit 42 Mode of Action of SSRIs
Exhibit 43 Global PE Market by Geography
Exhibit 44 Global PE Market by Geography ($ million)
Exhibit 45 Market Revenue Growth Rates Comparison by Geography
Exhibit 46 Global PE Market Lucrativeness by Geography 2022
Exhibit 47 PE Market in North America by Country 2016
Exhibit 48 Prevalence of PE in North America
Exhibit 49 PE Market in North America 2016–2022 ($ million)
Exhibit 50 PE Market in US 2016–2022 ($ million)
Exhibit 51 PE Market in Canada 2016–2022 ($ million)
Exhibit 52 Key PE Market Dynamics in North America
Exhibit 53 PE Market in Europe by Country 2016
Exhibit 54 Prevalence Trend of Prostate Cancer Holding High Associated Risk for PE Incidence in Europe 2012–2020 (thousand)
Exhibit 55 PE Market in Europe ($ million)
Exhibit 56 PE Market in Germany 2016–2022 ($ million)
Exhibit 57 PE Market in UK ($ million)
Exhibit 58 PE Market in France ($ million)
Exhibit 59 PE Market in Italy ($ million)
Exhibit 60 PE Market in Spain ($ million)
Exhibit 61 Key PE Market Dynamics in Europe
Exhibit 62 PE Market in APAC ($ million)
Exhibit 63 PE Market in Japan 2016–2022 ($ million)
Exhibit 64 PE Market in Australia ($ million)
Exhibit 65 PE Market in China ($ million)
Exhibit 66 PE Market in India ($ million)
Exhibit 67 Key PE Market Dynamics in APAC
Exhibit 68 PE Market in Latin America ($ million)
Exhibit 69 Key PE Market Dynamics in Latin America
Exhibit 70 PE Market in MEA 2016–2022 ($ million)
Exhibit 71 Key PE Market Dynamics in Latin America
Exhibit 72 Strategic Recommendation for Market Participants
TABLES
Table 1 Key Geographies Definition
Table 2 Key Caveats
Table 3 Currency Conversion 2013−2016
Table 4 Early Definitions of Premature Ejaculation
Table 5 Summary of PE Epidemiology Studies
Table 6 Recommended/Optional Questions to Establish Diagnosis and Treatment of PE
Table 7 Summary of PE Validated Questionnaires
Table 8 Summary of Commonly Recommended PE Drugs
Table 9 Key Pipeline PE Drug Molecules
Table 10 Key Dormant/Terminated/Withdrawn PE Pipeline Drug Molecules
Table 11 Epelsiban Product Profile
Table 12 IX-01 Product Profile
Table 13 DA-8031 Product Profile
Table 14 Recommended Drugs for PE Treatment
Table 15 Major Unmet Need in PE Market
Table 16 YOY Impact of Market Enablers 2016–2022
Table 17 Key Terminated/Withdrawn Investigational PE Drugs
Table 18 YOY Impact of Market Restraints 2016–2022
Table 19 Marketed PE Drugs with Meter-Dose Delivery Systems
Table 20 Pipeline Oxytocin Receptor Antagonists
Table 21 YOY Impact of Trends and Opportunities 2016–2022
Table 22 Global PE Market by Route of Administration 2016–2022 ($ million)
Table 23 Key Topical Therapy PE Drugs by Type of Formulation
Table 24 Global PE Market by Mechanism of Action 2016–2022 ($ million)
Table 25 Commonly Used Topical PE OTC Ester/Amide Anesthetic
Table 26 Global PE Market by Geography 2016–2022 ($ million)
Table 27 Key PE Campaigns Launched in Europe
Table 28 Competitive Structure Analysis of Global PE Market 2016
Table 29 Therapeutic Area and Products of Innovus
Table 30 Qualitative Summary of Global PE Market
Table 31 Quantitative Summary of Global PE Market by Geography ($ million)
Table 32 Quantitative Summary of Global PE Market by Geography (Revenue %)
Table 33 Quantitative Summary of Global PE Market by Route of Administration ($ million)
Table 34 Quantitative Summary of Global PE Market by Mechanism of Action ($ million)
